Acupoint Application With Herbal Fumigation and Wash for Preventing Diarrhea-induced Perianal Infection in Allo-HSCT Patients

Launched by RUIJIN HOSPITAL · Mar 30, 2025

Keywords

ClinConnect Summary

Diarrhea is one of the most common complications following hematopoietic stem cell transplantation (HSCT), with an incidence rate of 50%-70%. During HSCT, high-dose chemotherapy drugs can damage the intestinal mucosa, especially in allogeneic haploidentical hematopoietic stem cell transplantation, where the pre-treatment dosage is 5-10 times higher than that of conventional chemotherapy. This makes patients prone to chemotherapy-related diarrhea. Additionally, due to the patients' compromised immune systems, they are susceptible to other related types of diarrhea. Prolonged diarrhea can eas...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • First-time recipient of allogeneic hematopoietic stem cell transplantation.
• • Age between 14 and 70 years old, regardless of gender.
• • Primary disease type: Hematologic malignancies or aplastic anemia, with no restrictions on disease stage or remission status.
• • Transplant type: Matched sibling donor, haploidentical related donor, or unrelated donor.
• • Transplant conditioning regimen: Myeloablative, reduced-intensity, or non-myeloablative.
• • Informed consent and voluntary participation in this clinical study.
• Exclusion Criteria:
• • Presence of intestinal infection within 2 weeks prior to enrollment.
• • Previous diagnosis of inflammatory bowel disease or irritable bowel syndrome.
• • Pathologically or radiologically confirmed involvement of the primary disease in the intestines.
• • ECOG performance status ≥ 2, or presence of organ failure, rendering the patient unable to tolerate allogeneic hematopoietic stem cell transplantation.
• • Allergy to the trial medications or physical conditions unsuitable for sitz baths.
• • Individuals with mental disorders or those unable to provide informed consent.
• • Poor compliance, such as failure to implement the intervention measures for 3 consecutive days.
• • HIV-infected individuals, or those with a history of drug abuse or chronic alcoholism that may affect the evaluation of trial results.